

0040-4039(94)02417-0

An Unusual Formation of A Novel Spiroisoquinolone ring


D. Ghosh and D. E. Nichols*

Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47906


Abstract: A new spiro[napthalene-2(1H)-1'(2'H)-isoquinol-3-one] 2 was obtained after treatment of amidoalcohol 4 with polyphosphoric acid.

Spirocyclic compounds demonstrate diverse biological properties ranging from central nervous system activity to anti-tumor and anti-fungal effects.¹ This report describes the synthesis of a novel spiroisoquinolone.


In an effort to synthesize benzo[d]naptho[2,1-b]benzazepinone 1, spiro compound 2 was obtained. The synthetic strategy is illustrated in Scheme 1. The aminoalcohol 3 was prepared following a known procedure starting from 2-bromo-1-tetralone.² Reaction of 3 with 3,4-dimethoxyphenylacetyl chloride in the presence of triethylamine gave amidoalcohol 4. Since carbocations are more stable at a benzylic position it was anticipated that on acid cyclization 4 would give 1. Treatment with neat methanesulfonic acid at temperatures from 0 °C to 23 °C, yielded the dehydrated compound 5. To our surprise, however, treatment of 4 with polyphosphoric acid (PPA) at 100 °C for 90 min gave 2 as a crystalline solid. The structure of the compound was confirmed by spectroscopic analysis to be 6',7'-dimethoxy-3'-oxo-3,3',4,4'-tetrahydrospiro[napthalene-2(1H), 1'(2'H)-isoquinoline] (2).



A possible mechanism for formation of this spirocyclic compound is illustrated in Scheme 2. Protonation of 4 followed by dehydration leads to 5. The tautomeric iminium form of 5 then undergoes attack by the activated aromatic ring to form the spirocyclic 2. In order to test this hypothesis, enamide 5 was subjected to the same cyclization conditions (PPA, 100 °C). After a similar work-up, 2 was isolated as the only product. All the spectral and analytical data were in agreement with the proposed chemical structures.³



Scheme 2



Acknowledgments:

Support from NIMH (Grant # MH42705) is gratefully acknowledged.

References and Notes:

- (a) Bauer, V. J.; Duffy, B. J.; Hoffman, D.; Klioze, S. S.; Kosley, R. W. Jr.; McFadden, A.R.; Martin, L. L.; Ong, H. H. J. Med. Chem. 1976, 19, 1315. (b) Fish. P.V.; Pattender G. Tetrahedron Lett. 1988, 29, 3857. (c) Yamato, M.; Takeuchi, Y.; Tomozane, H. Synthesis 1990, 7, 569.
- (a) Riggs, R. M. Ph.D. Thesis, Purdue University, 1986. (b) Bowman, R.; Evans, D.; Guyett, J.; Nagy, H.; Weak, J.; Weyell, D. J. Chem. Soc. Perkin I. 1973, 438.
- 3. Analytical and Spectral Data:

2: mp 224-226 °C; ¹H NMR (CDCl₃, 500 MHz) δ 2.06 (m, 1H), 2.18 (m, 1H), 2.76 (d, *J* = 17 Hz, 1H), 3.00 (m, 2H), 3.48 (d, *J* = 16 Hz, 1H), 3.60 (d, *J* = 20 Hz, 1H, CHCO), 3.68 (d, *J* = 20 Hz, 1H, CHCO), 3. 79 (s, 3H, OCH₃), 3.90 (s, 3H, OCH₃), 6. 17 (broad s, 1H, NH), 6.66 (s, 1H, ArH), 6.75 (s, 1H, ArH), 7. 16 (m, 4H, ArH); ¹³C-APT (CDCl₃, 125.697 MHz) δ 26.10, 35.88, 35.95, 42.41 and 56.99 (aliphatic, all up); 107.32, 110.66, 126.60, 126.89, 129.05, 129.78 (aromatics, all up); 56.05 and 56.06 (OCH₃, down); 123.15, 130.50, 132.89, 134.17, 132.89, 134.17, 147.17, 147.97 and 148.53 (aromatics, all down), 170.59 (C=O); [quarternary and CH₂ are up; methyl and CH are down]; CIMS m/e 324 (M+1); Anal. for C₂₀H₂₁NO₃ (within ± 4%). **3**: mp (HCl) 188-189 °C (mixture of cis & trans); ¹H NMR(CDCl₃) δ 4.32 (d, *J* = 6.7 Hz, 1H, CH-trans), 4.52 (d, *J* = 3.9 Hz, 1H, CH-cis); *Chem. Abstr.* **1921**, *15*, 2093. **4**: mp 169-171 °C; ¹HNMR (CDCl₃) δ 3.54 (s, 2H, CH₂CO); Anal. C₂₀H₂₃NO₄ (± 4%). **5**: mp 156-158 °C; ¹HNMR (CDCl₃) δ 3.52 (d, *J* = 15 Hz, 1H, CHCO), 3.58 (d, *J* = 15 Hz, 1H, CHCO); HRMS calcd for C₂₀H₂₁NO₃ 324.1600, found 324.1610.

(Received in USA 9 November 1994; accepted 5 December 1994)